Observational Study to Assess Safety of H1N1 Pandemic Influenza Vaccine

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00950456
Recruitment Status : Completed
First Posted : July 31, 2009
Last Update Posted : October 9, 2015
Information provided by:
Ology Bioservices

Brief Summary:
The purpose of this observational study, which will be initiated as soon as the licensed H1N1 Pandemic Influenza Vaccine is used in a mass vaccination campaign, is to estimate the incidence of any medically-attended adverse events in all vaccinated subjects.

Condition or disease Intervention/treatment
Influenza Pandemic Influenza Biological: H1N1 Pandemic Influenza Vaccine (whole virion, Vero Cell-derived, inactivated)

Study Type : Observational
Actual Enrollment : 3216 participants
Observational Model: Ecologic or Community
Time Perspective: Prospective
Official Title: A Prospective Non-Interventional Observational Study to Assess the Safety of Two Vaccinations of a Vero Cell-Derived, Whole Virus H1N1 Pandemic Influenza Vaccine in Subjects Exposed to the Vaccine Through Policies by Governments or Health Authorities
Study Start Date : November 2009
Actual Primary Completion Date : December 2010
Actual Study Completion Date : February 2011

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Flu Flu Shot

Group/Cohort Intervention/treatment
H1N1 Pandemic Influenza Vaccine
Subjects will be enrolled and vaccinated according to national policy and standard practice.
Biological: H1N1 Pandemic Influenza Vaccine (whole virion, Vero Cell-derived, inactivated)
It is anticipated that subjects will receive two intramuscular injections approximately 3 weeks apart. The vaccine will be provided in two doses, one for adults, the other for children.
Other Name: CELVAPAN

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   2 Months and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
The enrollment of subjects in this study will follow national vaccination policy decisions in the UK.

Inclusion Criteria:

Male and female subjects, per indication on license or per official vaccine recommendations, will be eligible for participation in this study if:

  • They will be administered CELVAPAN (= Baxter´s H1N1 pandemic influenza vaccine)
  • They are 2 months of age or older at the time of first vaccine administration
  • Their medical history is available
  • The investigator believes they will comply with the foreseen vaccination schedule and will reliably observe signs or symptoms of adverse events during the observational period
  • They and/or their parent(s)/legal guardian(s) provide written informed consent, and assent where appropriate, prior to study entry according to national law

Exclusion Criteria:

Male and female subjects will be excluded from participation in this study if:

  • They have already been administered another H1N1 pandemic vaccine
  • They have any contraindication to vaccination (as per the Summary of Product Characteristics and/or relevant national immunization guidelines)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00950456

General Practice
Bludenz, Austria, 6700
General Practice
Fulpmes, Austria, 6166
General Practice
Hall in Tirol, Austria, 6060
General Practice
Innsbruck, Austria, 6020
Practice for Travel Medicine
Innsbruck, Austria, 6020
City Council (Magistrat) Klagenfurt (Health & Food Department)
Klagenfurt, Austria, 9020
General Practice
Kufstein, Austria, 6330
General Practice
Mariapfarr, Austria, 5571
General Practice
Oberperfuss, Austria, 6173
General Practice
Salzburg, Austria, 5020
General Practice
Telfs, Austria, 6410
Medical University of Vienna, Department of Internal Medicine I, Division of Infectious Diseases and Tropical Medicine
Vienna, Austria, 1090
Medical University of Vienna, Department of Specific Prophylaxis and Tropical Medicine
Vienna, Austria, 1090
Hanusch Hospital
Vienna, Austria, 1100
Wiener Gebietskrankenkasse (Health insurance center Vienna)
Vienna, Austria, 1100
General Practice
Voitsberg, Austria, 8570
General Practice
Wels, Austria, 4600
Sponsors and Collaborators
Ology Bioservices
Study Director: Baxter BioScience Medical Director Baxter Healthcare Corporation

Responsible Party: David Perry, MD; Sponsor´s signatory, Baxter Innovations GmbH Identifier: NCT00950456     History of Changes
Other Study ID Numbers: 820901
First Posted: July 31, 2009    Key Record Dates
Last Update Posted: October 9, 2015
Last Verified: May 2011

Additional relevant MeSH terms:
Influenza, Human
Orthomyxoviridae Infections
RNA Virus Infections
Virus Diseases
Respiratory Tract Infections
Respiratory Tract Diseases
Immunologic Factors
Physiological Effects of Drugs